Literature DB >> 21399479

Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala.

Nicaise Ndembi1, Raph L Hamers, Kim C E Sigaloff, Frederick Lyagoba, Brian Magambo, Bridget Nanteza, Christine Watera, Pontiano Kaleebu, Tobias F Rinke de Wit.   

Abstract

OBJECTIVE: To assess the emergence of transmitted HIV-1 drug resistance (TDR) in Kampala, Uganda, 10 years after the scale-up of antiretroviral treatment (ART) and to compare with a previous survey among antenatal clinic attendees in 2007 (reporting 0% TDR).
DESIGN: A cross-sectional survey was conducted among newly HIV-1 diagnosed, antiretroviral-naive young adults attending two large voluntary counseling and testing centers within the geographic area of Kampala.
METHODS: Proxy criteria for recent HIV-1 infection were used as defined by the WHO. Population sequencing of the pol gene was performed on plasma samples with HIV-1 RNA at least 1000 copies/ml. Surveillance drug resistance mutations (SDRMs) were identified according to the 2009 WHO list for surveillance of TDR. HIV-1 subtypes were designated using maximum likelihood phylogenetic reconstruction.
RESULTS: : Genotypic test results were obtained for 70 of 77 (90.9%) participants. SDRMs were identified in six samples yielding a prevalence of TDR of 8.6% (95% confidence interval 3.2-17.7%). Two had SDRMs to nucleoside reverse-transcriptase inhibitors (D67G and L210W), three had SDRMs to nonnucleoside reverse transcriptase inhibitors (G190A, G190S, and K101E), and one had SDRMs to protease inhibitors (N88D). Frequencies of HIV-1 subtypes were A (36/70, 51.4%), C ( two of 70; 2.9%), D (23/70, 32.9%), and unique recombinant forms (nine of 70, 12.9%).
CONCLUSION: This repeated survey suggests an increase in TDR in Kampala, compared with a previous survey. This finding justifies increased vigilance with respect to surveillance of TDR in areas in Africa where ART programs are rolled-out.

Entities:  

Mesh:

Year:  2011        PMID: 21399479     DOI: 10.1097/QAD.0b013e328346260f

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  33 in total

1.  Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda.

Authors:  Steven J Reynolds; Oliver Laeyendecker; Gertrude Nakigozi; Joel E Gallant; Wei Huang; Sarah E Hudelson; Thomas C Quinn; Kevin Newell; David Serwadda; Ronald H Gray; Maria J Wawer; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-26       Impact factor: 2.205

2.  Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?

Authors:  Guinevere Q Lee; Suzanne McCluskey; Yap Boum; Peter W Hunt; Jeffrey N Martin; David R Bangsberg; Xiaojiang Gao; P Richard Harrigan; Jessica E Haberer; Mark J Siedner
Journal:  J Acquir Immune Defic Syndr       Date:  2017-10-01       Impact factor: 3.731

3.  Low Rates of Transmitted Drug Resistance Among Newly Identified HIV-1 Seroconverters in Rural Rakai, Uganda.

Authors:  Steven J Reynolds; Victor Ssempijja; Ronald Galiwango; Anthony Ndyanabo; Gertrude Nakigozi; Fred Lyagoba; Jamirah Nazziwa; Andrew Redd; Susanna L Lamers; Ron Gray; Maria Wawer; David Serwadda; Thomas C Quinn
Journal:  AIDS Res Hum Retroviruses       Date:  2016-11-28       Impact factor: 2.205

4.  Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013.

Authors:  Suzanne M McCluskey; Guinevere Q Lee; Kimia Kamelian; Annet Kembabazi; Nicholas Musinguzi; Mwebesa B Bwana; Conrad Muzoora; Jessica E Haberer; Peter W Hunt; Jeffrey N Martin; Yap Boum; David R Bangsberg; P Richard Harrigan; Mark J Siedner
Journal:  AIDS Patient Care STDS       Date:  2018-07       Impact factor: 5.078

Review 5.  Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature.

Authors:  Julie E Myers; Barbara S Taylor; Rita A Rojas Fermín; Emily Virginia Reyes; Catherine Vaughan; Lina José; Carmen Javier; Ramona Franco Estévez; Yeycy Donastorg Cabral; Arelis Batista; Yolanda Lie; Eoin Coakley; Scott M Hammer; Karen Brudney
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-23       Impact factor: 2.205

6.  Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009.

Authors:  G M Hunt; J Ledwaba; A E Basson; J Moyes; C Cohen; B Singh; S Bertagnolio; M R Jordan; A Puren; L Morris
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

7.  Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.

Authors:  Gert U van Zyl; Lisa M Frenkel; Michael H Chung; Wolfgang Preiser; John W Mellors; Jean B Nachega
Journal:  AIDS       Date:  2014-11-28       Impact factor: 4.177

8.  Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya.

Authors:  Amin S Hassan; Shalton M Mwaringa; Clare A Obonyo; Helen M Nabwera; Eduard J Sanders; Tobias F Rinke de Wit; Patricia A Cane; James A Berkley
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-11       Impact factor: 2.205

9.  Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda.

Authors:  Guinevere Q Lee; David R Bangsberg; Conrad Muzoora; Yap Boum; Jessica H Oyugi; Nneka Emenyonu; John Bennett; Peter W Hunt; David Knapp; Chanson J Brumme; P Richard Harrigan; Jeffrey N Martin
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-29       Impact factor: 2.205

10.  Short communication: Transmitted HIV drug resistance in antiretroviral-naive pregnant women in north central Nigeria.

Authors:  Godwin E Imade; Atiene S Sagay; Beth Chaplin; Philippe Chebu; Jonah Musa; Jonathan Okpokwu; Donald J Hamel; Ishaya C Pam; Oche Agbaji; Jay Samuels; Seema Meloni; Jean-Louis Sankale; Prosper Okonkwo; Phyllis Kanki
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-22       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.